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Judith S. Hochman, MD, b and Gervasio A. Lamas, MDa,d Miami Beach, FL; New York, NYIntroduction There is epidemiological evidence that metal contaminants may play a role in the development of
atherosclerosis and its complications. Moreover, a recent clinical trial of a metal chelator had a surprisingly positive result in
reducing cardiovascular events in a secondary prevention population, strengthening the link between metal exposure and
cardiovascular disease (CVD). This is, therefore, an opportune moment to review evidence that exposure to metal pollutants,
such as arsenic, lead, cadmium, and mercury, is a significant risk factor for CVD.
Methods We reviewed the English-speaking medical literature to assess and present the epidemiological evidence that 4
metals having no role in the human body (xenobiotic), mercury, lead, cadmium, and arsenic, have epidemiologic and
mechanistic links to atherosclerosis and CVD. Moreover, we briefly review how the results of the Trial to Assess Chelation
Therapy (TACT) strengthen the link between atherosclerosis and xenobiotic metal contamination in humans.
Conclusions There is strong evidence that xenobiotic metal contamination is linked to atherosclerotic disease and is a
modifiable risk factor. (Am Heart J 2014;168:812-22.)The result of a recent clinical trial of a metal chelator
showing reduced cardiovascular events in a secondary
prevention population highlights the potential connec-
tion between metal pollutants and cardiovascular disease
(CVD). This is, therefore, an opportune moment to
review the causal link between metal exposure and CVD.
The most commonly used terms for metal pollutants,
heavy metals or toxic heavy metals, refer to specific
density, atomic weight, atomic number, or other
chemical properties. We have chosen to use the term
xenobiotic, to denote a foreign chemical substance
found within an organism, thus, xenobiotic metal.Definitions
Xenobiotic metals have no biological role at any dose.
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,
imany others. We will focus on these 4 toxic, xenobiotic
metals that are ranked among the top 10 on the
current Agency for Toxic Substances and Disease
Registry Priority List of Hazardous Substances.1
Arsenic, lead, and mercury are ranked as the top 3
hazardous substances.
Lead
Distribution. Lead is the most common toxic element.
Volcanic activity and geochemical weathering are the
greatest natural sources. Lead-based paints, gasoline
additives, food-can soldering, battery making, and sol-
dered joints of drinking water pipe systems represent
anthropogenic sources of lead in the environment.2,3
Recommendations to limit lead paints since 1978 have led
to substantial reductions in childhood lead toxicity.4
Many children, however, continue to live in houses with
either nonintact lead-based paint or high levels of lead in
dust. Exposure to lead also occurs through airborne
emissions and occupational exposures, water, and foods
or occasionally through the use of alternative health care
products, such as herbal remedies5 (Table). Tetraethyl
lead as a gasoline additive for land-based vehicles has now
been largely banned worldwide. However, it is still
present in aviation fuel for piston engine aircraft. Particles
of lead suspended in the atmosphere, along with fuel-
based and other sources of lead,3,6 can represent a source
of continued exposure.
Absorption, body distribution, and excretion.
Approximately 30% to 40% of inhaled and 5% to 10% of
Table. Metal exposure, half-life, ingestion, excretion, and ways to measure
Metal Exposure Half-life Ingestion Excretion Measure
Lead Food, water, air, gasoline additives,
food-can soldering, lead-based paints,
ceramic glazes, drinking water pipe
systems, folk remedies
In blood
36 d; in bones
20-30 y
Inhalation with 30%-40%
absorbed; ingestion with
5% absorbed in adults
and up to 50% in children
Urine, sweat,
hair, nails
Blood level
x-ray fluorescence
of bone, urine level
Cadmium Contaminated food (leafy vegetables,
grains, organ meats, and crustaceans),
drinking water, inhalation of polluted air,
occupational exposure in industries,
tobacco smoke
In liver 4-19 y;
in kidneys, 6-38 y
Inhalation with 40%-50%
absorbed; ingestion with
3%-7% absorbed
No efficient
excretory
mechanism,
small amounts
excreted via urine
Blood level, urine
level, biopsy of the
liver, kidneys, hair
Mercury Contaminated fish, meat and organ
tissue of marine mammals or feral
wildlife, dental amalgams, skin-lightening
creams, antiseptic facial products,
mercury-containing laxatives or diuretics,
teething powders, latex paint
Elemental: in
blood, 1-3 d; in
the whole body,
1-3 wk
Inorganic: in
blood, 1-3 wk
Organic: in
blood and the
whole body, 50 d
Elemental: inhalation with
80% absorbed, ingestion
with 0.01% absorbed
Inorganic: inhalation or
inhalation with 10%
absorbed, skin with
2%-3% absorbed
Organic: inhalation or
inhalation with 95%-100%
absorbed
Metabolized in
the liver and
excreted through
the bile duct 10%
excreted via urine
Blood level,
urine level, toenail
level
Arsenic Contaminated fish, tobacco smoke,
arsenic treated wood, ingestion of
high-arsenic drinking water
Inorganic: in
blood, 4-6 h
Methylated: in
blood 20-30 h
Inhalation with 40%-60%
absorbed, ingestion with
95% absorbed
Urine, nails, hair Blood level, urine
level, hair and nail
levels
Solenkova et al 813
American Heart Journal
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intestinal (GI) absorption, however, can reach as high as
30% to 50% in children3 (Table). Once absorbed, 99% of
lead binds to red blood cells, and 1% remains in serum.3
The half-life of lead in the bloodstream is relatively short
(36 days), whereas in bones, it is 20 to 30 years.3
Absorbed lead is excreted from the body via urine, sweat,
hair, and nails.2,3
Exposure evaluation. Blood lead assesses acute
exposure to lead.3 Blood lead levels, however, represent
only recent short-term exposures and account for
approximately 1% to 5% of total body lead burden; the
rest is stored in bone and other tissues.3 Bone acts as an
endogenous source of lead by continuous release of the
metal to the plasma, long after exposure has ended, when
the rate of bone turnover increases. Indeed, noninvasive
x-ray fluorescence of bone is the most accurate technique
to assess body lead burden.7,8 Urine lead may be used to
assess lead exposure and for monitoring of therapy for
lead toxicity.
Blood lead levels have exhibited a steady decline over
the last decades, concurrent with the mandated discon-
tinuation of leaded gasoline for ground vehicles. The
mean blood lead level in the US population 30 years ago
was 12.8 μg/dL, which decreased to 1.45 μg/dL more
recently, with 99% of US adults having blood lead levels
b10 μg/dL.9 Epidemiological data strongly suggest that
there may be no safe threshold level for lead, however.10
Cardiovascular effects. Increased cardiovascular
mortality has been attributed to both elevated bloodand bone lead levels with stronger association shown for
bone levels.11,12 (Figure 1A). Weisskopf et al13 analyzed
the association between tertiles of patella and tibia lead
and mortality in 868 male participants of the Veterans
Affairs Normative Aging Study. After multivariable adjust-
ments, when compared to the first tertile, participants in
the third tertile were more likely to die of all causes
(hazard ratio [HR] 2.52, 95% CI 1.17-5.41, P = .02) and
cardiovascular causes (HR 5.63, 95% CI 1.73-18.3, P =
.003) and nearly 10 times more likely to die of ischemic
heart disease (HR 8.37, 95% CI 1.29-54.4, P = .01). In the
second National Health and Nutrition Examination Survey
(NHANES), Lustberg and Silbergeld14 reported that
subjects with blood lead levels of 20 to 29 μg/dL had
increased all-cause mortality (relative risk [RR] 1.46, 95%
CI 1.14-1.86) and circulatory mortality (RR 1.39, 95% CI
1.01-1.91) compared with those having blood lead levels
b10 μg/dL.
Menke et al10 studied 13,946 adult participants of the
NHANES III with blood lead levelsb0.48μmol/L (10 μg/dL)
followed up for up to 12 years. After multivariate
adjustment, the risk of cardiovascular events was signifi-
cantly greater in participants with the highest tertile of lead
exposure (≥0.17 μmol/L or 3.62 μg/dL), compared with
those in the lowest tertile (b0.09μmol/L or 1.94μg/dL). All-
cause mortality was higher by 25% (HR 1.25, 95% CI 1.04-
1.51) in the third tertile versus the first tertile, whereas
cardiovascular mortality was higher (HR 1.55, 95% CI 1.08-
2.24), mortality frommyocardial infarction was higher (HR
1.89, 95% CI 1.04-3.43), and mortality from stroke was
higher by more than 2-fold (HR 2.51, 95% CI 1.20-5.26).10
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lead was associated with an increased prevalence of
peripheral arterial disease (PAD), even at levels below
current safety standards.11
The association of lead exposure with hypertension
is one of the best established cardiovascular effects of
this metal.15,16 Meta-analyses of 61 original studies,
including approximately 60,000 participants, 17
showed that a doubling of blood lead was associated
with an increase in systolic blood pressure (SBP) of
1.0 to 1.25 mm Hg and diastolic blood pressure (DBP)
of 0.6 mm Hg.15 Although small in magnitude, these
increases in SBP and DBP could have clinical
relevance in large populations.
Lead exposure has also been linked to dyslipidemia and
atherosclerosis.14,18,19 Experimental and human autopsy
studies showed an association between lead exposure
and aortic atherosclerotic plaque burden.14,19-21 There
are some interesting findings that support the association
of lead with atherosclerosis. For example, the cardiopro-
tective antioxidant activity of high-density lipoprotein is
partially mediated by paraoxonase activity, an enzyme
that is closely bound to the high-density lipoprotein
particle and involved in inhibition of low-density
lipoprotein (LDL) oxidation. Lead as well as other metals
can inactivate paraoxonase and, therefore, promote LDL
oxidation and atherosclerosis development.22-24
Cadmium
Distribution
Cadmium is considered one of the most toxic
environmental substances due to its ubiquity, toxicity,
and long half-life. Exposure to cadmium occurs through
inhalation (particularly in active cigarette smokers),
water consumption, industrial exposure, and contam-
inated food (Table). Tobacco plants are highly efficient
in absorbing cadmium from soil and accumulating it in
the leaf.25 Therefore, any exposure to tobacco smoke
leads to high exposure to cadmium,26 and smokers
have cadmium levels that are at least twice as high as
those of nonsmokers.25,27 High levels of cadmium can
be found in vegetables, fruits, and grains, with the
highest levels in greens and potatoes. Shellfish and
organ meats contain elevated cadmium concentrations
as well, and agricultural fertilizer has also been reported
to contain cadmium.25,28,29
Absorption, body distribution, and excretion.
Approximately 40% to 50% of inhaled and 3% to 7% of
ingested cadmium is absorbed. Similar to lead, GI absorption
of cadmium is greater in the young25,30 (Table). Intestinal
cadmium absorption occurs through a transporter shared
with iron, and when accompanied by iron deficiency, GI
cadmium absorption may increase.31 Once absorbed,
cadmium is protein bound via erythrocytes or albumin
and undergoes hepatic conjugation to metallothionein, a
cysteine-rich protein.25 This cadmium-metallothionein-cadmium complex then accumulates in the kidneys and
may cause renal impairment.25 Cadmium is also stored in
bones, pancreas, adrenals, testes, and placenta.25
Cadmium has no efficient excretory mechanism. It is
excreted in the urine, but it remains bound to
metallothionein, which is almost completely reab-
sorbed in the renal tubules.25 Cadmium half-life in the
liver is between 4 and 19 years and, in the kidneys, is
between 6 and 38 years.25,27
Exposure evaluation
Cadmium levels can be measured in blood, urine,
liver, kidney, hair, and other tissues.25 Blood cadmium
level is indicative of recent exposure.25 The geometric
mean level in occupationally nonexposed adults in the
United States is 0.315 μg/L. In heavy smokers, this level
may be as high as 1.58 μg/L (Table).
Urine cadmium reflects mainly total body burden,
although urine levels change with recent exposure as
well. In the US general population, the geometric mean
urinary cadmium level in adults is 0.232 μg/L (or 0.247 μg/g
creatinine)32 (Table).
Cardiovascular effects. Cadmium is associated with
cardiovascular and all-cause mortality (Figure 1B). Menke
et al28 reported that every 2-fold increase in creatinine
adjusted urinary cadmium levels in men is associated with
an increase in risk of all-cause (HR 1.28, 95% CI 1.15-1.23)
and cardiovascular mortality (HR 1.21, 95% CI 1.07-1.36).
The risk of coronary artery disease (CAD)–associated
mortality was also increased (HR 1.36, 95% CI 1.11-1.66).
Although these associations were not observed in
women, other studies showed cardiovascular mortality
to be associated with urinary cadmium levels in both
genders.33,34 In a review published recently by Tellez-
Plaza et al,35 based on 12 studies the pooled RRs for CVD,
CAD, stroke, and PAD were 1.36 (95% CI 1.11-1.66), 1.30
(95% CI 1.12-1.52), 1.18 (95% CI 0.86-1.59), and 1.49 (95%
CI 1.15-1.92), respectively.35 The pooled RRs for CAD in
men, women and never smokers were 1.29 (1.12, 1.48),
1.20 (0.92, 1.56), and 1.27 (0.97, 1.67), respectively.35
These are modest in magnitude but quite consistent.
Cadmium has also been associated with PAD in both
men and women.11,35-37 Blood and urine cadmium levels
were 16% (95% CI 4.7-28.7) and 36% (95% CI 1-83)
higher,11,37 respectively, in patients with PAD. After
adjustment for age, sex, race, smoking status, and urinary
creatinine, the odds ratio for PAD comparing the highest
versus lowest quartile of urine cadmium distribution was
3.05 (95% CI 0.97-9.58).37
The largest epidemiologic examination of the associa-
tion between cadmium exposure and blood pressure
change was based on the 1999-2004 NHANES survey.38
Among 15,332 participants older than 20 years, Tellez-
Plaza et al38 reported an association of blood, but not
urine, cadmium levels with a modest elevation of blood
pressure. The geometric mean of blood cadmium was
Figure 1
A
B
A, Lead exposure: odds ratios for mortality for blood/bone lead.B, Cadmium exposure: odds ratios for CVD ormortality for urine cadmium.C, Mercury
exposure: odds ratios for CVDordeath.D, Arsenic exposure: odds ratios for CVDand death for urine arsenic. References cited in this figure: 98, 99, 100.
KIHD 200598, HPFS99, Kakehashi River Basin100.
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Volume 168, Number 63.77 nmol/L (0.42 μg/L). Participants in the 90th percentile
of blood cadmium distribution had 1.36 mm Hg (95% CI
0.24-3.24) higher SBP and 1.68 mm Hg (95% CI 0.57-2.78)
higher DBP levels when compared to participants in the
10th percentile of blood cadmium distribution.Mercury
Distribution. Mercury has been ranked as the third
most toxic environmental hazard after arsenic and lead.1
Common sources of mercury exposure include proximity
to mercury mining sites, recycling facilities, medical or
municipal incinerators, coal-fired power plants, or
mercury-containing latex paint.39 Dietary sources include
fresh water fish or seafood40 with high mercury content,
high-fructose corn syrup, rice, and other dietary prod-ucts. In addition, dental amalgam is a historic source of
mercury exposure.38 There have also been reports of
mercury contamination in beauty products, laxatives, and
infant products.39,41 Another potential source of mercury
is thimerosal-containing vaccines. Thimerosal, a contro-
versial ethylmercury compound that has been used as a
preservative in vaccines, has been completely removed
from pediatric vaccines and mostly removed from
adult products.
Absorption, body distribution, and excretion.
Approximately 80% of inhaled and 0.01% of ingested
elemental mercury is absorbed.38 For inorganic mercury,
absorption of inhaled versus ingested mercury is equal
(10%), whereas 2% to 3% of inorganic mercury is
absorbed through the skin.38 Organic mercury (most
Figure 1
C
D
(Continued).
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completely (95%-100%) absorbed and is the most toxic
form of mercury that is distributed to all organs and
tissues including brain and placenta38 (Table). Elimina-
tion of organic mercury from the body occurs through
either demethylation to inorganic mercury or degrada-
tion to L-cystein complex in bile. Approximately 10% of
organic mercury is excreted through the urine. Selenium,
vitamin C, and vitamin E can decrease toxic effects of
mercury by multiple mechanisms.42-44
Exposure evaluation. Blood, urine, and toenail levels
of mercury have been used to estimate mercury
exposure38 (Table). Blood mercury levels peak sharply
during exposure and then decrease rapidly.45 The mean
total mercury levels in whole blood and urine of the
general population are approximately 1 to 8 μg/L and 4to 5 μg/L, respectively.46 Mercury levels as high as 200
μg/L have been reported in individuals with high fish
intake,46 which is striking in the context of US
occupational exposures being limited to b15 μg/L.38,47
Urine mercury may be used for assessment of inorganic
mercury exposure, as organic mercury represents only a
small fraction of urinary mercury. Urine mercury levels
may vary greatly during the day and from day to day in
the same individual, as well as show inter-individual
variability, even in a setting of constant exposure.38
Current Occupational Safety and Health Administration
recommendations require urinary mercury levels not to
exceed 35 μg mercury per gram of creatinine.47
Cardiovascular effects. When evaluating the associ-
ation of mercury levels and CVD, it is important to note
that this relationship may be confounded by fish
Figure 2
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cardiovascular risk (Figure 1C).
In 1995, Salonen et al48 reported an association between
high levels of mercury exposure via freshwater fish
consumption and risk of acute myocardial infarction
(AMI), all-cause, and cardiovascular mortality. Men in the
highest tertile of hair mercury content when compared to
the lowest tertile had RR of fatal or nonfatal AMI of 1.69
(95% CI 1.03-2.76, P = .038), RR of CVD of 2.9 (95% CI 1.2-
6.6, P = .014), and RR of death from any cause of 2.3 (95%
CI 1.4-3.6, P b .001). The RR of coronary death in this study
was not associated with hair mercury content. In a case-
control study, Guallar et al49 showed an association
between higher levels of toenail mercury and risk of
nonfatal AMI. More recently, Mozaffarian et al44 found no
association between toenail mercury and CAD, stroke, or
total CVD inparticipantswith either normal or low levels of
selenium, which may protect against mercury toxicity.
Data regarding a relationship between mercury expo-
sure and blood pressure changes are inconsistent.50-53
Studies of chronic occupational mercury exposure inminers revealed a 46% increase in incidence of hyper-
tension when compared to age-matched controls.54
Correlations have been reported between hair or blood
mercury and elevated blood pressure.50,51Arsenic
Distribution. Arsenic is highly toxic to human health.1
Inorganic and most toxic forms of arsenic (arsenate and
arsenite) are found in soils, crops, andwater, particularly in
groundwater from deep wells, often used as drinking
water. These compounds are also found in environmental
tobacco smoke and arsenic-treated wood, used in most
outdoor wooden structures in the United States.55 High
levels of arsenic are present in agricultural fertilizer that is
used for soil treatment; therefore, vegetables and fruits, if
grown in this soil, contain high levels of arsenic55 (Table).
Arsenic has also been used as an additive to poultry feed
to inhibit parasites. Arsenic is emitted by coal-burning
power plants. As for organic forms of arsenic, large
amounts of arsenobetaine or arsenocholine are found in
818 Solenkova et al
American Heart Journal
December 2014contaminated fish; however, these forms are consid-
ered to be essentially nontoxic.55-57
Absorption, body distribution, and excretion. The
primary routes of arsenic absorption are gastrointestinal
and respiratory55 (Table). Approximately 40% to 60% of
inhaled and 95% of ingested arsenic is absorbed.55
Arsenic metabolism includes 2 main reactions: conver-
sion of arsenate to arsenite by oxidation/reduction
reactions forming glutathione-arsenic complexes and
methylation that occurs mainly in the liver producing
water soluble monomethylarsinic acid and dimethylarsi-
nic acid that are eliminated through the urine. Arsenic
metabolism is an area of active investigation, as differ-
ences in methylation of arsenic have been associated with
differences in health outcomes, including CVD.55,58,59
Exposure evaluation. Because arsenic is cleared from
the blood within a few hours of exposure, measurement
of blood arsenic can only be used to assess a very recent
exposure55 (Table). Typical values in nonexposed
individuals should be b1 μg/L.60
Urine is considered to be the most reliable body sample
to detect arsenic exposure. The American Conference of
Governmental Industrial Hygienists considers urine
arsenic b35 μg/L to be acceptable for nontoxic exposed
individuals. Yet, other reports61 suggest that there may
be no safe threshold of arsenic exposure. Arsenic can be
detected in urine of people with no known exposure.55
This could be due to high consumption of certain seafood
that contain a nontoxic organic form of arsenic,
arsenobetaine.55 Therefore, the measurement of spe-
ciated urinary arsenic, rather than total urinary arsenic, is
preferred for assessments of cardiovascular toxicity.
Finally, arsenic tends to accumulate in nails and hair,
wherein acceptable levels of arsenic are b1 ppm.60
Cardiovascular effects. There is only limited
evidence on the relationship between arsenic and
cardiovascular morbidity and mortality (Figure 1D). The
only prospective cohort study, published recently by
Moon et al,62 reported that long-term exposure to low to
moderate arsenic levels is associated with CVD incidence
and cardiovascular mortality. Participants of this study
had a median urinary arsenic level of 9.7 μg/g creatinine,
with a range from 1 to 183.4 μg/g creatinine and
interquartile range between 5.8 and 15.7 μg/g creatinine.
The hazard ratios for CVD mortality, CAD mortality, and
stroke mortality per interquartile range were 1.65 (95% CI
1.20-2.27; P b .001 for trend), 1.71 (95% CI 1.19-2.44, P b
.001 for trend), and 3.03 (95% CI 1.08-8.50, P b .001 for
trend), respectively. The association of arsenic with CVD
mortality was stronger in participants with diabetes.
Evidence is also accumulating on the association between
higher levels of arsenic exposure and cardiovascular
morbidity and mortality in Bangladesh.63
High levels of well-water arsenic exposure are recog-
nized as being causative in the development of PAD,37,64,65such as blackfoot disease. This is a severe form of PAD
endemic to Taiwan characterized by thromboangiitis
obliterans, severe arteriosclerosis, and high levels of vessel
wall arsenic.37,64,65 However, the generalizability of these
findings is limited, due to the nature of the exposure (deep
well water) and the extremely high estimated levels of
arsenic exposure.
Finally, although the literature is limited, there is
evidence to suggest a positive relationship between
arsenic exposure and hypertension.66Hypothetical mechanisms of metal toxicity
There are general mechanisms that apply to all toxic
metals and specific mechanisms that are idiosyncratic to
the individual metal in question. These mechanisms
center on oxidative stress. Although the science under-
lying these mechanisms is accurately quoted, attribution
of benefit to metal chelation because of these mecha-
nisms has to be considered speculative. Moreover, the
oxidative-stress = oxidative-damage hypothesis has been
challenged as well.
Oxidative stress results from an imbalance between the
production and detoxification of reactive oxygen species
(ROS). The toxicity of ROS is basedon their ability to oxidize
intracellular and extracellular structures such as proteins,
lipids, and nucleic acids (Figure 2). Several enzyme systems
are known to protect the body against ROS. These enzymes
include superoxide dismutase, catalase, glutathione perox-
idase, paraoxonase, thioredoxin, heme oxygenase, and
others. Glutathione peroxidase is of particular interest.
Many metals have electron-sharing properties and,
therefore, are capable of forming covalent bonds with
sulfhydryl groups of proteins (eg, glutathione, cystein,
homocysteine, metallothionein, and albumin).67 By
binding to glutathione, these metals deplete its levels
and, therefore, increase the intracellular concentration of
ROS. The consequences include promotion of lipid
peroxidation; cell membrane damage; DNA damage;
oxidation of aminoacids in proteins and, therefore,
changes in their conformation and function; and inacti-
vation of enzymes. According to current concepts of
atherogenesis, oxidative modification of LDL, a free
radical-driven lipid peroxidation process, is an early
event in atherosclerosis development.68
Many metals have been shown to increase lipid
peroxidation.69,70 In addition, metal-related, ROS-mediated
changes include microtubule destruction, mitochondrial
damage by disruption of the membrane potential, inhibi-
tion of adenosine triphosphate production, followed by
dysfunction of ion transporters such as Ca–adenosine
triphosphatase and Na–K–adenosine triphosphatase caus-
ing changes in calcium homeostasis.71
By binding to sulfhydryl groups of proteins not involved in
the detoxification of ROS,metalsmay cause other biological
impairments. Lead causes endothelial dysfunction by
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decreasing nitric oxide production.72,73 Mercury has also
been reported to impair nitric oxide metabolism by
binding to sulfhydryl (SH) groups of NF-kB and
changing its effects on gene expression and, thus,
resulting in decreased expression of inducible nitric
oxide synthase.74 Cadmium has been shown to inhibit
endothelial and calcium-calmodulin constitutive nitric
oxide synthase as well.75 Arsenic exposure was linked
to impairment of nitric oxide production and increased
generation of ROS, perhaps by uncoupling of endothe-
lial nitric oxide synthase production.76
There are additional, idiosyncratic mechanisms of toxic-
ity. Thus, lead, competing with zinc, binds to sulfhydryl
groups of delta-aminolevulinic acid dehydratase (the
enzyme involved in heme metabolism), preventing binding
of delta-aminolevulinic acid dehydratase to aminolevulinic
acid,77 generating ROS.78 Lead has also been shown to
promote endothelial release of endothelin, to elevate serum
levels of norepinephrine, angiotensin-converting enzyme,
and thromboxane and to decrease production of prostacy-
clin.79,80 All these changes may mediate vascular constric-
tion. In addition, lead, being one of the calcium-like
elements, competes with calcium for transport by channels
and pumps in endoplasmic reticulum. Lead may also
substitute for calcium in calcium-dependent processes and
can interact with calmodulin.
Arsenic inhibits pyruvate and α-ketoglutarate dehydro-
genases, important enzymes of gluconeogenesis and
glycolysis.81 It can also replace phosphate in glycolysis,
generating arseno-3-phosphoglycerate instead of 1,3-
bisphosphoglycerate, which leads to uncoupling of oxi-
dative phosphorylation.81 Moreover, arsenic has been
linked to increased intravascular inflammation by up-
regulating interleukin 6; tumor necrosis factor α; and
monocyte chemotactic protein, vascular cell adhesion
molecule and intercellular adhesion molecule.82 Fur-
thermore, arsenic inhibits expression of peroxisome
proliferator–activated receptor γ causing hyperglyce-
mia and dyslipidemia.83
Macrophages and endothelial cells take up cadmium by
endocytosis causing foam cell production followed by
foam cell necrosis and endothelial cell disruption
followed by endothelial cell necrosis. Once the endothe-
lial layer is disrupted, cadmium reaches smooth muscle
cells and accumulates there, activating smooth muscle
cell proliferation and apoptosis. Cadmium may also
substitute for iron and copper in proteins that contain
these biologically necessary metals. As a result, iron and
copper, after being released from its usual binding
proteins, may produce ROS, as both elements can be
more easily involved in reduction-oxidation reactions.84
Cadmium is also associated with perturbations in
inflammation and coagulation, including elevated blood
C-reactive protein and fibrinogen in a general US
population, even after adjustment for other CVD riskfactors such as smoking.82,85,86 Moreover, cadmium
exposure has been associated with elevations of media-
tors or markers of systemic inflammation, including
interleukin 6, tumor necrosis factor α, and vascular cell
adhesion molecule 1.87
Oxidative stress, metals, and diabetes
Patients with diabetes are thought to be especially
susceptible to oxidative stress. The formation of ad-
vanced glycation end-products, advanced lipoxygenation
products, and protein oxidation products require none-
nzymatically, metal catalyzed oxygen chemistry. These
oxidized and cross-linked complexes are long lived and
form the basis of diabetes complications, activating the
receptor for advanced glycation end-products88 and
multiple other downstream inflammatory cascades,89-91
and although the transition elements most closely
associated with these reactions are iron and copper,
xenobiotic transition elements, such as cadmium and
others (cobalt and tungsten),92 might be also involved.
Potential interventions
Chelation therapy with EDTA (edetate disodium) has
been used to treat atherosclerotic disease since 1956,93
without a solid scientific base. In 2002, the Cochrane
Collaborative94 reported that there was insufficient
evidence to make a recommendation for or against
chelation therapy. Yet patients continued to seek, and
practitioners to use, EDTA to prevent or treat atheroscle-
rotic disease of the coronaries, carotids, and peripheral
arteries. In 2002, TACT, a 2 × 2 factorial trial testing 40
disodium EDTA infusions versus placebo and oral high-
dose multivitamins and minerals versus oral placebo was
designed95 and funded. TACT enrolled 1,708 patients96
who had sustained a prior myocardial infarction, were at
least 50 years old, and had a creatinine of≤2.0mg/dL. TACT
administered 55,222 infusions of EDTA-based chelation or
placebo. EDTA chelation significantly reduced, by 18% (p=
0.035), a combined cardiovascular endpoint, with a 5-year
number needed to treat of 18. In 633 patients who had
diabetes,97 a diagnosis associated with a strong prooxidant
state, the reduction in events was greater, with a 41%
reduction in events and a number needed to treat of 6.5
patients over 5 years (unadjusted P = .0002). Thus TACT
provides a strong inferential support for the conclusion that
environmental metal pollution may be a potent and
modifiable risk factor for atherosclerotic disease.
Conclusions
Prudent public health measures should be taken to fully
assess, thenminimize, the public's exposure to xenobiotic
metals. In addition, given the present state of the science,
it appears reasonable to consider the results of the
recently published chelation trial (TACT) as biologically
plausible and, in selected patients, especially those with
820 Solenkova et al
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December 2014diabetes and coronary disease, actionable. This will be the
topic of the next trial, TACT2, now in its planning phase.
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